Wall Street analysts expect that AveXis, Inc. (NASDAQ:AVXS) will announce earnings of ($1.51) per share for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for AveXis’ earnings. The lowest EPS estimate is ($1.91) and the highest is ($0.69). AveXis posted earnings per share of ($0.92) during the same quarter last year, which would indicate a negative year over year growth rate of 64.1%. The business is scheduled to report its next earnings results on Thursday, March 15th.

According to Zacks, analysts expect that AveXis will report full-year earnings of ($6.23) per share for the current financial year, with EPS estimates ranging from ($6.61) to ($5.36). For the next financial year, analysts expect that the firm will post earnings of ($5.92) per share, with EPS estimates ranging from ($7.33) to ($2.90). Zacks’ EPS calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for AveXis.

AveXis (NASDAQ:AVXS) last issued its quarterly earnings data on Thursday, November 9th. The company reported ($1.52) EPS for the quarter, missing the consensus estimate of ($1.48) by ($0.04). During the same quarter in the previous year, the firm posted ($0.87) earnings per share.

AVXS has been the subject of several analyst reports. Barclays initiated coverage on AveXis in a report on Wednesday, September 6th. They set an “overweight” rating and a $124.00 price objective for the company. Nomura initiated coverage on AveXis in a report on Monday, August 28th. They set a “reduce” rating and a $52.00 price objective for the company. Zacks Investment Research upgraded AveXis from a “hold” rating to a “buy” rating and set a $112.00 price objective for the company in a report on Tuesday, October 24th. Instinet initiated coverage on AveXis in a report on Tuesday, August 29th. They set a “reduce” rating and a $52.00 price objective for the company. Finally, Bank of America decreased their price objective on AveXis from $115.00 to $112.00 and set a “buy” rating for the company in a report on Friday, November 10th. Three investment analysts have rated the stock with a sell rating, three have issued a hold rating and thirteen have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $110.67.

In other AveXis news, VP Andrew F. Knudten sold 2,000 shares of the stock in a transaction dated Monday, December 4th. The stock was sold at an average price of $94.48, for a total transaction of $188,960.00. Following the sale, the vice president now directly owns 7,000 shares of the company’s stock, valued at approximately $661,360. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Brian K. Kaspar sold 15,000 shares of the stock in a transaction dated Monday, October 9th. The stock was sold at an average price of $101.46, for a total value of $1,521,900.00. The disclosure for this sale can be found here. Over the last three months, insiders sold 52,340 shares of company stock worth $5,172,298. 18.60% of the stock is owned by insiders.

A number of institutional investors and hedge funds have recently made changes to their positions in the business. FMR LLC grew its position in AveXis by 13.1% during the 2nd quarter. FMR LLC now owns 4,705,433 shares of the company’s stock worth $386,598,000 after purchasing an additional 544,475 shares during the period. BlackRock Inc. grew its position in AveXis by 34.7% during the 2nd quarter. BlackRock Inc. now owns 2,301,229 shares of the company’s stock worth $189,069,000 after purchasing an additional 592,843 shares during the period. Vanguard Group Inc. grew its position in AveXis by 31.8% during the 2nd quarter. Vanguard Group Inc. now owns 1,575,205 shares of the company’s stock worth $129,419,000 after purchasing an additional 380,396 shares during the period. Janus Henderson Group PLC grew its position in AveXis by 52.2% during the 3rd quarter. Janus Henderson Group PLC now owns 1,027,221 shares of the company’s stock worth $99,363,000 after purchasing an additional 352,456 shares during the period. Finally, State Street Corp grew its position in shares of AveXis by 104.2% during the 2nd quarter. State Street Corp now owns 1,000,001 shares of the company’s stock valued at $82,163,000 after acquiring an additional 510,189 shares during the period. 92.88% of the stock is currently owned by institutional investors.

Shares of AveXis (NASDAQ:AVXS) opened at $93.50 on Wednesday. AveXis has a twelve month low of $44.68 and a twelve month high of $108.27.

TRADEMARK VIOLATION NOTICE: “Zacks: Analysts Expect AveXis, Inc. (AVXS) to Post -$1.51 EPS” was originally reported by American Banking News and is the property of of American Banking News. If you are accessing this news story on another domain, it was copied illegally and republished in violation of United States & international copyright legislation. The original version of this news story can be viewed at https://www.americanbankingnews.com/2017/12/06/zacks-analysts-expect-avexis-inc-avxs-to-post-1-51-eps.html.

AveXis Company Profile

AveXis, Inc is a clinical-stage gene therapy company. The Company operates through the developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.

Get a free copy of the Zacks research report on AveXis (AVXS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for AveXis (NASDAQ:AVXS)

Receive News & Ratings for AveXis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AveXis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.